ADEKUNBI IMALENOWA: Open Payments
NPI 1073144937 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,632 in 80 payments from 12 companies in 2025. Trend: 2023 $770 · 2024 $1,023 · 2025 $1,632
Food & beverage: $1,520Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $402 |
| Teva Pharmaceuticals USA, Inc. | 18 | $371 |
| Janssen Pharmaceuticals, Inc | 17 | $284 |
| Vanda Pharmaceuticals Inc. | 9 | $175 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $113 |
| Alkermes, Inc. | 4 | $79 |
| Lundbeck LLC | 4 | $64 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $29 |
Products named: INGREZZA, INVEGA SUSTENNA, FANAPT, UZEDY, AUSTEDO XR, CAPLYTA, ARISTADA, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
